Protalix BioTherapeutics (PLX) Liabilities from Discontinued Operations (2014 - 2016)

Protalix BioTherapeutics' Liabilities from Discontinued Operations history runs 3 years deep, the most recent figure standing at 293000.0 for Q2 2016.

• On a quarterly basis, Liabilities from Discontinued Operations changed N/A year-over-year to 293000.0 in Q2 2016; TTM through Jun 2016 was 293000.0, a N/A change from a year earlier, with the FY2015 full-year figure at 1568000.0, down 97.03% from the prior year.
• Liabilities from Discontinued Operations climbed to 293000.0 in Q2 2016 per PLX's latest filing, from 128000.0 in the prior quarter.
• Across five years, Liabilities from Discontinued Operations topped out at 52830000.0 in Q4 2014 and bottomed at 128000.0 in Q1 2016.
• The 3-year median for Liabilities from Discontinued Operations is 930500.0 (2015), against an average of 13704750.0.
• Biggest YoY gain for Liabilities from Discontinued Operations was 97.03% in 2015; the steepest drop was 97.03% in 2015.
• Year by year, Liabilities from Discontinued Operations stood at 52830000.0 in 2014, then slumped by 97.03% to 1568000.0 in 2015, then sank by 81.31% to 293000.0 in 2016.
• Per Business Quant, the three latest PLX Liabilities from Discontinued Operations figures stand at 293000.0 (Q2 2016), 128000.0 (Q1 2016), and 1568000.0 (Q4 2015).